title: Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after curative resection and to examine the factors associated with the prognosis in a single center.
  
  
  METHODS
  Between January 1995 and July 2006, 169 patients who had undergone curative resection were diagnosed with recurrent HCC. Of these, 114 patients underwent TACE as first-line therapy and were followed until July 2007.
  
  
  RESULTS
  At the time of resection, the mean tumor size was 4.8 + or - 2.9 cm, and 96 (84.2%) patients had a single tumor. Single nodular recurrence was observed in 53 (46.5%) patients. The mean size of the recurrent HCC was 2.1 + or - 1.2 cm. The disease-free survival after TACE was 46.0%, 16.7%, and 13.4% at 1, 2, and 3 years, respectively. The overall survival after TACE was 77.8%, 53.6%, and 31.6% at 1, 3, and 5 years, respectively. Cox regression analysis revealed that the Edmonson grade and time to recurrence (>6 months) independently affected the disease-free survival (both P < 0.05). The time to recurrence (>6 months) and tumor-node-metastasis stage were associated with overall survival (both P < 0.05). Only 1 lethal complication (biliary sepsis) occurred after TACE.
  
  
  CONCLUSIONS
  TACE seems to be a safe, effective treatment for recurrent HCC after curative resection.
authors: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
authors: Jong Won
authors: JW
authors: Choi
authors: Jun Yong
authors: JY
authors: Park
authors: Sang Hoon
authors: SH
authors: Ahn
authors: Ki Tae
authors: KT
authors: Yoon
authors: Heung-Kyu
authors: HK
authors: Ko
authors: Do Yun
authors: DY
authors: Lee
authors: Jong Tae
authors: JT
authors: Lee
authors: Kyung Sik
authors: KS
authors: Kim
authors: Jin Sub
authors: JS
authors: Choi
authors: Kwang-Hyub
authors: KH
authors: Han
authors: Chae Yoon
authors: CY
authors: Chon
authors: Do Young
authors: DY
authors: Kim
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D012449:Safety; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents